Drug Details

General Information of the Drug (ID: DR7874)
Name
Diosgenin
Synonyms
DIOSGENIN; 512-04-9; Nitogenin; UNII-K49P2K8WLX; Spirost-5-en-3-ol, (3b,25R)-; (20R,25R)-Spirost-5-en-3beta-ol; K49P2K8WLX; CHEBI:4629; (25R)-spirost-5-en-3beta-diol; MFCD00016887; NSC 33396; Spirost-5-en-3-beta-ol, (25R)-; (3beta,25R)-spirost-5-en-3-ol; (25R)-Spirost-5-en-3beta-ol; SP 37; C27H42O3; (2'R,4S,5'R,6aR,6bS,8aS,8bR,9S,11aS,12aS,12bS)-5',6a,8a,9-Tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol; (25R)-14beta,17beta-spirost-5-en-3beta-ol; 3beta-Hydroxy-5-spirostene; nitrogen in; CCRIS 6803; 22alpha-Spirost-5-en-3beta-ol; Dioscorea sapogenin; Diosgenin,(S); (7S,8S,10S,13S,15S,18S,22S,3R,12R,14R,19R)-3,13,15,19-tetramethyl-11-oxaspiro[ 2H-3,4,5,6-tetrahydropyran-6,6'-pentacyclo[10.8.0.0<2,9>.0<4,8>.0<13,18>]icosa ne]-24-en-22-ol; YUV; EINECS 208-134-3; DISOGENIN; BRN 0094582; Diosgenin, >=93%; 3A-Hydroxy-5-spirostene; SCHEMBL83359; 5-19-03-00030 (Beilstein Handbook Reference); (25R)-5-Spirosten-3A-ol; CHEMBL412437; (25R)-5-Spirosten-3beta-ol; DTXSID00895074; (25R)-Spirost-5-en-3.beta-ol; HY-N0177; ZINC6857614; LMST01080037; SBB058140; AKOS015961083; ACN-034765; CS-5303; MCULE-6739922044; NCGC00386027-01; Spirost-5-en-3-ol, (3-beta,25R)-; AS-13640; ST097775; AB0090307; N1715; S2291; Spirost-5-en-3beta-ol, (25R)- (8CI); C08898; J10028; M03858; Spirost-5-en-3-ol, (3beta,25R)- (9CI); 512D049; Q-100574; Q1107734; BRD-K28690501-001-02-1; Diosgenin, European Pharmacopoeia (EP) Reference Standard; UNII-5E5W122QCR component WQLVFSAGQJTQCK-VKROHFNGSA-N; (2R,5'R)-5'-tetramethylspiro[[?]-2,2'-tetrahydropyran]ol; NCGC00386027-01_C27H42O3_Spirost-5-en-3-ol, (3beta,25R)-; (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hepatocellular carcinoma [ICD-11: 2C12] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.071
 
MDCK Permeability
 -4.893
 
PAMPA
 - - -
 
HIA
 - - -
 
Distribution
VDss
 -0.036
 
PPB
 83.8%
 
BBB
 - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 +++
CYP2B6 inhibitor
 +++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +
 
Excretion
CLplasma
 17.361
 
T1/2
 1.515
Toxicity
DILI
 ++
 
Rat Oral Acute Toxicity
 -
 
FDAMDD
 ++
 
Respiratory
 -
 
Human Hepatotoxicity
 +
 
Ototoxicity
 +
 
Drug-induced Nephrotoxicity
 -
 
Drug-induced Neurotoxicity
 - -
 
Hematotoxicity
 - - -
 
Genotoxicity
 - - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C27H42O3
PubChem CID
99474
Canonical SMILES
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1
InChI
1S/C27H42O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28H,6-15H2,1-4H3/t16-,17+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1
InChIKey
WQLVFSAGQJTQCK-VKROHFNGSA-N
CAS Number
CAS 512-04-9
ChEBI ID
CHEBI:4629
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Morroniside      Cornus officinalis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
                    Experimental
                    Result(s)		 Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis.
Target and Pathway
Target(s) S-phase kinase-associated protein 2 (SKP2)  Molecule Info  [3]
References
Reference 1 Diosgenin inhibited the expression of TAZ in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018 Sep 10;503(3):1181-1185.
Reference 2 Combination of Morroniside and Diosgenin Prevents High Glucose-Induced Cardiomyocytes Apoptosis. Molecules. 2017 Jan 19;22(1):163.
Reference 3 Diosgenin Exerts Antitumor Activity via Downregulation of Skp2 in Breast Cancer Cells. Biomed Res Int. 2020 Jun 16;2020:8072639.
 Download Picture         KEGG Link